ImmunoIVD SPOT-it TREC & SMN1 Screening Kit

ImmunoIVD, a Stockholm-based diagnostic company specializing in severe combined immunodeficiency (SCID) newborn screening, has launched the CE IVD marked SPOT-it TREC & SMN1 Screening kit in the EU. The real-time qPCR assay is designed to simultaneously screen or SCID and spinal muscular atrophy (SMA) in newborns using DNA extracted from fresh, dried blood spots sampled on filter paper. The assay is based on the same plate-stacking procedure as the SPOT-it SCID screening assays, making it efficient and affordable for small to medium sized screening laboratories, a company spokesperson said. SCID screening is performed by semi-quantification of T-cell receptor excision circle, while SMA screening is performed through the qualitative detection of exon 7 of the SMN1 gene, according to the company's website.